ReviewAnalytical and bioanalytical chemistry2026
Advances in spatial omics for the analysis of prostate cancer.
Review in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cold solvent washing enhances AFADESI-MSI spatial lipidomics and lipid metabolism profiling in pancreatic cancer.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer is one of the most common malignancies in men and is marked by extensive clinical and molecular heterogeneity. Although genomic and transcriptomic studies have revealed recurrent alterations and lineage plasticity, these approaches lack spatial resolution and therefore cannot capture the microenvironmental context that underpins tumor progression and therapeutic resistance. Spatial omics technologies have emerged as transformative tools by integrating high-dimensional molecular profiling with preserved tissue architecture. Advances in spatial transcriptomics, proteomics, epigenomics, and metabolomics now permit the mapping of gene expression, protein signaling, chromatin accessibility, modifications, and folding, along with metabolic gradients at cellular to subcellular resolution. Spatial analysis of prostate cancer has revealed key features of disease progression, including stromal remodeling, immune evasion, lipid metabolic rewiring, and therapy-resistant niches. This review highlights recent spatial omics technologies, their emerging integrative and clinical applications in prostate cancer, and the future challenges in standardization, data integration, and clinical translation.
Indexed as
Identifiers
41723338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.